Neo Health (OTC) has partnered with the University of Technology Sydney (UTS) to offer pharmaceutical industry placements for their Master of Pharmacy and Master of Good Manufacturing Practice students.
The placement program focuses on providing students with a unique opportunity to delve into the dynamic world of pharmaceuticals. Sanna Fatima Saleem, a recent participant in Neo Health (OTC)’s student placement program, expressed her enthusiasm, stating, “My time at Neo Health (OTC) was extremely valuable, with the amazing team fostering an environment for learning (…) enabling me to achieve the best placement outcomes.”
This collaboration reflects Neo Health (OTC)’s commitment to contributing to the education and growth of future pharmaceutical leaders. By actively engaging with UTS, Neo Health (OTC) aims to bridge the gap between academic knowledge and real-world applications, preparing students to navigate the complexities of the pharmaceutical landscape with confidence.
Watch this video where Sanna describes her experience at Neo Health (OTC).
A leading Australian healthcare company, Neo Health, has joined the Generic and Biosimilar Medicines Association (GBMA) as its first ‘Affiliate Member’, marking the ongoing growth of the peak body for affordable medicines.
Reflecting the diversity of the Australian healthcare eco-system, GBMA created the entry-level membership tier for medicine and technology manufacturers, suppliers, industry associations and patient groups, with aligned values and views.
Neo Health is an Australian based company specialising in over the counter (OTC), prescription, wellness, and personal care solutions. Their aim is to provide products for all therapeutic categories, across multiple channels and global markets to help people live healthier, happier lives.
Neo Health has links across the affordable medicines sector and an Affiliate membership of the GBMA was a ‘positive and strategic’ fit, according to Managing Director, Mr Aman Madan.
“We share GBMA’s core objectives to ensure all Australians have secure supply and timely access to high-quality, safe and affordable medicines” Mr Madan said.
Chief Executive Officer of the GBMA, Ms Marnie Peterson, said Neo Health had joined the organisation at an important time in the medicine policy landscape1 with cost-of-living pressures and the increasing rate of chronic disease among Australians2.
“The burden of chronic disease rests heavily on the health and the hip pocket of many Australians,” Ms Peterson said.” One in five Australians have two or more chronic diseases,3 and most depend on multiple medicines and services, from multiple healthcare professionals.”
Ms Peterson said the GBMA is working closely with the Government, members, and our stakeholders, to develop and implement effective policy reforms that better protect patients against the cost-of-living increases whilst ensuring they have affordable and timely access to the medicines and healthcare services they need.
“We welcome Neo Health to our mission to do everything we can to improve the health and financial wellbeing of all Australian patients,” Ms Peterson said.
About the GBMA
The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
About Neo Health (OTC)
Neo Health (OTC) is a proudly Australian-owned company with experience in innovation and leadership spanning more than 25 years, servicing pharmaceutical companies, pharmacy chains and grocery retailers. Neo Health develops and licenses over-the-counter, prescription, and complementary medicines, medical devices, niche, and innovative products for the Australian market.
1 https://www.pbs.gov.au/info/news/2022/12/refreshed-national-medicines-policy 2 Treasury.gov.au/policy-topics/measuring-what-matters/dashboard/prevalence-chronic-conditions 3 The 2020-21 chronic conditions data sourced from Australian Bureau of Statistics, National Health Survey 2020-21
Neo Health (OTC) Managing Director Aman Madan participated in the B20 summit held in New Delhi, India on 25th-27th August 2023. He was part of the Australian delegation that contributed to the global economic dialogue, adding the perspective of the pharmaceutical industry to help formulate strategic economic policies.
This year’s theme was Responsible, Accelerated, Innovative, Sustainable, Equitable (R.A.I.S.E) Businesses. R.A.I.S.E is rooted in the belief that the G20 business community should raise the bar for equitable growth by committing to business practices that are responsible and grounded in sustainable practices.
In addition to a special session with Prime Minister of India Narendra Modi, the event also witnessed attendance from distinguished speakers and guests from G20 nations.
The Business 20 (B20) is the official G20 dialogue forum with the global business community. Established in 2010, B20 is among the most prominent Engagement Groups in G20, with companies and business organizations as participants.
The B20 aims to deliver concrete actionable policy recommendations on priorities by each rotating presidency to spur economic growth and development. The B20 bases its work on Task Forces (TFs) and Action Councils (ACs) entrusted to develop consensus-based policy recommendations to the G20 and to international organizations and institutions.
Aman Madan, Neo Health (OTC), Managing Director attended the 9th edition of iPHEX (International Exhibition of Pharma and Healthcare) hosted by Pharmaceuticals Export Promotion Council of India (Pharmexcil) with the support of the Ministry of Commerce & Industry, Government of India during 5-7th July 2023 in Hyderabad, India.
Aman was an integral part of the CEO Roundtable among the participants from G20 countries on the topic – ‘Potential Collaborations among G20 Countries: Business Prospects for India.’
Here’s a sneak peek from his speech at the CEO roundtable.
iPHEX brings together the drugs, pharmaceutical and healthcare industry – all under one roof. One of the largest showcases of Indian pharmaceutical products and technologies to a global audience. 400+ overseas buyers from focus areas are invited to participate in the exhibition. It offers the industry majors from India and all across the world a great platform to connect and do business. It provides an opportunity to meet new and existing customers actively looking for new suppliers, or looking to assess the current progress of existing projects.
Aman Madan: Building Opportunities With New-Age Technologies In Pharmaceuticals
The significance of the healthcare and pharmaceutical industry is hardly unfamiliar to the world, especially after the covid-19 pandemic. Responsible for saving millions of lives almost every day, the segment however has also some gaps pertaining to the availability of OTC products for the immediate needs, and when the patient requires it. It usually takes not less than 12- 24 months to get new products shelf ready.
Fascinated by these challenges and being eager to offer end-to-end services to customers, Aman Madan channeled his entrepreneurial abilities to lay the foundation of Neo Health (OTC) in 2010. When the world succumbed to the wrath of the COVID-19, Aman leveraged his decades-long experience across the pharmaceutical industry to make the best out of existing opportunities and streamline his business process to get an edge over the competitors. Under Aman’s guidance and strategic leadership, Neo Health (OTC) has not only been able to dominate the Australian OTC drugs market, but is also exponentially growing to become one of the leading forces in the global pharmaceutical domain.
Read the excerpt of Aman’s interview with CEO Insights magazine here.